These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 21095445

  • 1. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [Abstract] [Full Text] [Related]

  • 2. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Nov; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 3. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I, Chan L.
    Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
    [Abstract] [Full Text] [Related]

  • 4. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 5. Can the early elimination of calcineurin inhibitors result in clinical benefits?
    Weir MR.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S16-20. PubMed ID: 21095444
    [Abstract] [Full Text] [Related]

  • 6. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 7. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 8. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M, Van Der Giet M.
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [Abstract] [Full Text] [Related]

  • 9. Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen.
    Yilmaz M, Nart A, Sen S, Tasli F, Uslu A, Hur E, Ozkahya M, Hoscoskun C, Toz H.
    Nephrology (Carlton); 2010 Sep; 15(6):653-8. PubMed ID: 20883287
    [Abstract] [Full Text] [Related]

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 11. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B.
    Transpl Int; 2004 Jul 27; 17(6):279-85. PubMed ID: 15221123
    [Abstract] [Full Text] [Related]

  • 12. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK, Weir MR.
    Curr Opin Organ Transplant; 2008 Dec 27; 13(6):614-21. PubMed ID: 19060552
    [Abstract] [Full Text] [Related]

  • 13. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T, Argudo A, Peña-Cala MC.
    Transplant Proc; 2011 Dec 27; 43(6):2216-9. PubMed ID: 21839237
    [Abstract] [Full Text] [Related]

  • 14. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 15. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T, Segovia R, Castro L, Roblero JP, Estela R.
    Transplant Proc; 2011 Nov 27; 43(6):2307-10. PubMed ID: 21839260
    [Abstract] [Full Text] [Related]

  • 16. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators.
    Transplantation; 2011 Aug 27; 92(4):410-8. PubMed ID: 21697773
    [Abstract] [Full Text] [Related]

  • 17. Current immunosuppressive approaches in liver transplantation.
    Iacob S, Cicinnati VR, Beckebaum S.
    Panminerva Med; 2009 Dec 27; 51(4):215-25. PubMed ID: 20195232
    [Abstract] [Full Text] [Related]

  • 18. [Minimization or avoidance of calcineurin inhibitors after renal transplantation].
    Xue C, Ji ZG.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun 27; 31(3):280-3. PubMed ID: 19621509
    [Abstract] [Full Text] [Related]

  • 19. Calcineurin inhibitors in liver transplantation: to be or not to be.
    Castroagudín JF, Molina E, Varo E.
    Transplant Proc; 2011 Jun 27; 43(6):2220-3. PubMed ID: 21839238
    [Abstract] [Full Text] [Related]

  • 20. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
    Sert M, Celik A, Kural K, Ersan S, Ataca P, Atila K, Cavdar C, Sifil A, Bora S, Gulay H, Camsari T.
    Ren Fail; 2011 Jun 27; 33(8):789-94. PubMed ID: 21787153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.